Immunoglobulin

ApprovedSmall molecule

Immunoglobulin is one of 712 small molecule programs targeting Chronic Inflammatory Demyelinating Polyneuropathy. It is currently in Approved.

Indications

Total Trials

Active Trials

711

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Inflammatory Demyelinating PolyneuropathyActive, not recruiting

Japanese EncephalitisActive, not recruiting

Neuropathic PainActive, not recruiting

Unverricht-Lundborg DiseaseActive, not recruiting

Bronchopulmonary DysplasiaActive, not recruiting

Chronic Inflammatory Demyelinating PolyradiculoneuropathyActive, not recruiting

Psychiatric DisorderActive, not recruiting

Thrombocytopenic PurpuraActive, not recruiting

ThrombocytopeniaActive, not recruiting

Toxic Epidermal NecrolysisActive, not recruiting

Chronic Inflammatory Demyelinating PolyneuropathyPhase 2

Active, not recruiting

Japanese EncephalitisPhase 2

Active, not recruiting

Neuropathic PainPhase 2

Active, not recruiting

Unverricht-Lundborg DiseasePhase 3

Active, not recruiting

Bronchopulmonary DysplasiaPhase 2

Active, not recruiting

Chronic Inflammatory Demyelinating PolyradiculoneuropathyPhase 2

Active, not recruiting

Psychiatric DisorderPhase 3

Active, not recruiting

Thrombocytopenic PurpuraPhase 1/Phase 2

Active, not recruiting

ThrombocytopeniaApproved

Active, not recruiting

Toxic Epidermal NecrolysisPhase 3

Active, not recruiting

Showing 10 of 34 indications

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Immunoglobulin

Sanofi

Approved

1 2

Activella

Eli Lilly

Preclinical

—3

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 4

Tricor

JJagotec

Preclinical

1 5

Nitrostat

VViatris Specialty LLC

Preclinical

1 6

Statin

Bristol-Myers Squibb

Preclinical

1 7

Achromycin V

WWyeth-Lederle Vaccines

Olokizumab

1 9

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

1 10

Selenium

SSWOG Cancer Research Network

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Systemic Sclerosis

NCT03630211

Post-ApprovalRecruiting

Newly Diagnosed

NCT05520892

Q4 2026

Phase 2Active, not recruiting

Antibody-Mediated Rejection

NCT05156710

N/ANot yet recruiting

Guillain-Barre Syndrome

NCT05114941

Q1 2027

Phase 3Recruiting

Immunodeficiency

NCT06954441

Phase 3Recruiting

Efficacy and Safety

NCT04656184

Clinical

Trials by Indication[1]

Neuropathy4 trials

Subcutaneous Immunoglobulin Treatment for Multifocal Motor Neuropathy

Completed·UUniversity of Aarhus·Phase 2·NCT00268788·10 enrolled

Intravenous Immunoglobulin Therapy for Small Fiber Neuropathy

Completed·AAcademisch Ziekenhuis Maastricht·Phase 2·NCT02637700·60 enrolled

IVIG in Painful Sensory Neuropathy

Not yet recruiting·SSorlandet Hospital HF·Phase 4·NCT06183008·20 enrolled

Show 1 more trial

IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3

Completed·—·Phase 2·NCT03401073·20 enrolled

Antibody-mediated Rejection3 trials

Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation

Terminated·—·Phase 2·NCT01895127·11 enrolled

Transplant Antibody-Mediated Rejection: Guiding Effective Treatments

Terminated·IImperial College London·Phase 3·NCT03994783·3 enrolled

BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

Active, not recruiting· Sanofi logo

Sanofi·Phase 2·NCT05156710·48 enrolled

Treatment3 trials

IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements

Completed·UUniversity of Minnesota··NCT02414490·30 enrolled

H-IVIG Treatment for Severe H1N1 2009

Completed·TThe University of Hong Kong·N/A·NCT01617317·34 enrolled

IVIG Versus Plasmapheresis in the Treatment of Guillian Barrie Syndrome Patients

Completed·—·Phase 2/3·NCT05104762·81 enrolled

Intravenous3 trials

Intravenous Immunoglobulins as Effective Treatment in Sydenham's Chorea

Completed·UUniversity of Cape Town·N/A·NCT00615797·20 enrolled

Efficacy of Intravenous Immunoglobulin in Management of Rh and ABO Incompatibility Disease

Unknown status·—·Phase 1·NCT03130517·30 enrolled

Effect of Pre-emptive Intravenous Immunoglobulin (IVIG) on the Incidence of Septic Episodes in Pediatric Burn Patients

Completed·—·Phase 2/3·NCT05134792·30 enrolled

Thrombocytopenic Purpura2 trials

Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients

Terminated·MMomenta Pharmaceuticals, Inc.·Phase 1/2·NCT03866577·50 enrolled

Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10

Completed· CSL Behring logo

CSL Behring·Phase 3·NCT00168038·58 enrolled

49 more indications

Pilot Study2 trials

Feasibility and Safety of Immunoglobulin (Ig) Treatment in COPD Outpatients With Frequent Exacerbations: Pilot Study 1

Completed·OOttawa Hospital Research Institute·Phase 2·NCT03018652·22 enrolled

Ig PRx in AECOPD: Pilot Study

Completed·OOttawa Hospital Research Institute·Phase 2·NCT02690038·48 enrolled

Pregnancy2 trials

IVIg Plus Low Dose rhTPO for ITP in Pregnancy

Unknown status·PPeking University People's Hospital·Phase 2·NCT05634824·50 enrolled

The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss

Unknown status·SShanghai First Maternity and Infant Hospital·Phase 4·NCT02990403·500 enrolled

Psychosis2 trials

Study of Immunotherapy in Autoantibody Positive Psychosis

Completed·UUniversity of Cambridge·N/A·NCT02449746·10 enrolled

IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2

Recruiting·UUniversity of Cambridge·Phase 2·NCT03194815·70 enrolled

Alzheimer's Disease2 trials

Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT00299988·24 enrolled

A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease

Completed·IInstituto Grifols, S.A.·Phase 2/3·NCT01561053·347 enrolled

Immunodeficiency2 trials

V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency

Recruiting·OOn Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.·Phase 3·NCT06954441·50 enrolled

Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral Immunodeficiency

Withdrawn·GGreen Cross Corporation·Phase 3·NCT03492710

AIN2 trials

Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome

Withdrawn·CChafic Karam·Phase 2·NCT05701189

A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)

Completed·AAnnexon, Inc.·Phase 1·NCT04035135·14 enrolled

Kawasaki Disease2 trials

Infliximab (Remicade) for Patients With Acute Kawasaki Disease

Completed·UUniversity of California, San Diego·Phase 1·NCT00271570·24 enrolled

A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study)

Unknown status·NNational Taiwan University Hospital·Phase 3·NCT03200561·100 enrolled

CIDP1 trial

Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC)

Recruiting·UUniversity of Aarhus·Phase 4·NCT04589299·60 enrolled

Thrombocytopenia1 trial

Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS)

Unknown status·QQin Ning·Phase 4·NCT05604859·350 enrolled

Epilepsy1 trial

IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy

Terminated·MMayo Clinic·Phase 3·NCT02697292·17 enrolled

Miscarriage1 trial

Trial of the Efficacy of Intravenous Immunoglobulin for Treating Women With Unexplained Secondary Recurrent Miscarriage

Completed·RRigshospitalet, Denmark·Phase 3·NCT00722475·82 enrolled

Combination Therapy1 trial

Intravenous Immunoglobulin in Combination Therapy With Antibacterial Agents for SSI of the Lower Digestive Tract

Withdrawn·MMulticenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group·N/A·NCT00511212·60 enrolled

Mucopolysaccharidosis1 trial

A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)

Withdrawn· Takeda logo

Takeda·Phase 4·NCT05494593

Pemphigus1 trial

Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus

Terminated·NNYU Langone Health·Phase 2·NCT00483119·9 enrolled

Psychiatric Disorder1 trial

Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)

Completed·NNational Institute of Mental Health (NIMH)·Phase 3·NCT00001768·10 enrolled

Transplant Recipient1 trial

Subcutaneous Ig in Allogeneic Stem Cell Transplant Recipients

Completed·UUniversity Health Network, Toronto·N/A·NCT03401268·20 enrolled

Randomised Controlled Trial1 trial

A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis

Terminated·GGuy's and St Thomas' NHS Foundation Trust·Phase 3·NCT02398994·2 enrolled

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT00001287·60 enrolled

Unverricht-Lundborg disease1 trial

Intravenous Immunoglobulin for Unverricht-Lundborg Disease.

Unknown status·AAzienda Socio Sanitaria Territoriale di Mantova·Phase 3·NCT03351569·1 enrolled

Dermatomyositis1 trial

Subcutaneous Immunoglobulin (Hizentra) in Patients With Dermatomyositis: A Proof of Concept Study

Terminated·TThomas Jefferson University·Phase 1·NCT02271165·2 enrolled

Toxic Epidermal Necrolysis1 trial

Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.

Completed·NNihon Pharmaceutical Co., Ltd·Phase 3·NCT01696500·10 enrolled

Tics1 trial

Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml

Completed·PProthya Biosolutions·Phase 3·NCT01985373·23 enrolled

Tic Disorder1 trial

Stem Cell Transplant for Immunologic or Histiocytic Disorders

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00176865·19 enrolled

Kidney Transplant1 trial

A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation

Completed·—·Phase 1/2·NCT01594424·10 enrolled

Pneumonia1 trial

The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia

Unknown status·PPeking Union Medical College Hospital·Phase 2/3·NCT04261426·80 enrolled

Multiple System Atrophy1 trial

Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins

Completed·UUniversity of Massachusetts, Worcester·Phase 2·NCT00750867·9 enrolled

Idiopathic Pulmonary Fibrosis1 trial

Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis

Recruiting·AArgyrios Tzouvelekis·Phase 3·NCT07299695·196 enrolled

Guillain-Barre syndrome1 trial

Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome

Not yet recruiting·TThe First Affiliated Hospital of Zhengzhou University·N/A·NCT05114941·204 enrolled

Hyperbilirubinemia1 trial

Efficacy of High-dose Intravenous Immunoglobulin Therapy for Hyperbilirubinemia Due Rh Hemolytic Disease

Completed·OOswaldo Cruz Foundation·Phase 4·NCT00288600·92 enrolled

Chronic Inflammatory Demyelinating Polyradiculoneuropathy1 trial

Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Completed·UUniversity of Aarhus·Phase 2·NCT01017159·30 enrolled

Japanese encephalitis1 trial

Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis

Completed·UUniversity of Liverpool·Phase 2·NCT01856205·22 enrolled

Efficacy and Safety1 trial

A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT04656184·84 enrolled

Systemic Sclerosis1 trial

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

Recruiting·PPaul Szabolcs·Phase 2·NCT03630211·8 enrolled

Neuropathic Pain1 trial

Intravenous Immunoglobulin (IVIG) for Resistant Neuropathic Pain

Unknown status·UUniversity of Calgary·Phase 2·NCT00850005·12 enrolled

Autoimmune Encephalitis1 trial

To Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-modal MRI

Completed·FFirst Affiliated Hospital of Zhejiang University··NCT03530462·22 enrolled

Myelopathy1 trial

A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy

Terminated·—·Phase 4·NCT01561755·12 enrolled

Stem Cell Transplant1 trial

Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00230035

Phase 11 trial

Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants

Active, not recruiting·AArialys Therapeutics·Phase 1·NCT06753955·6 enrolled

Newly Diagnosed1 trial

Two Regimens of IVIG in the Treatment of Newly Diagnosed ITP in Children

Recruiting·FFujian Medical University Union Hospital·Phase 4·NCT05520892·580 enrolled

End-Stage Renal Disease1 trial

A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation

Completed· Roche logo

Roche·Phase 1·NCT02586051·24 enrolled

Antibiotic Therapy1 trial

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)

Recruiting·MMonash University·Phase 2/3·NCT07202052·900 enrolled

Bronchopulmonary Dysplasia1 trial

IVIG Trial for the Treatment of Bronchopulmonary Dysplasia

Recruiting·IInternational Peace Maternity and Child Health Hospital·Phase 2·NCT06925360·20 enrolled

Myasthenia Gravis1 trial

Subcutaneous Immunoglobulin for Myasthenia Gravis

Completed·UUniversity Health Network, Toronto·Phase 2·NCT04728425·30 enrolled

Biliary Atresia1 trial

Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 1/2·NCT01854827·30 enrolled

Langerhans Cell Histiocytosis1 trial

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

Recruiting·NNorth American Consortium for Histiocytosis·Phase 2/3·NCT02205762·1,400 enrolled

COVID-191 trial

Randomised Evaluation of COVID-19 Therapy

Recruiting·UUniversity of Oxford·Phase 3·NCT04381936·70,000 enrolled

Immunotherapy1 trial

Immunotherapy and Paraneoplastic Neurological Syndromes

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT02343211·17 enrolled

Optic Neuritis1 trial

Intravenous Immunoglobulin Therapy in Optic Neuritis

Completed·NNational Eye Institute (NEI)·Phase 3·NCT00000117

Down syndrome1 trial

Mechanistic Investigation of Therapies for Down Syndrome Regression Disorder

Completed·UUniversity of Colorado, Denver·Phase 2·NCT05662228·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 71 trial records for Immunoglobulin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Immunoglobulin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Immunoglobulin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Sanofi

Immunoglobulin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q1 2027

Trials by Indication[1]

Neuropathy4 trials

Antibody-mediated Rejection3 trials

Treatment3 trials

Intravenous3 trials

Thrombocytopenic Purpura2 trials

Pilot Study2 trials

Pregnancy2 trials

Psychosis2 trials

Alzheimer's Disease2 trials

Immunodeficiency2 trials

AIN2 trials

Kawasaki Disease2 trials

CIDP1 trial

Thrombocytopenia1 trial

Epilepsy1 trial

Miscarriage1 trial

Combination Therapy1 trial

Mucopolysaccharidosis1 trial

Pemphigus1 trial

Psychiatric Disorder1 trial

Transplant Recipient1 trial

Randomised Controlled Trial1 trial

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

Unverricht-Lundborg disease1 trial

Dermatomyositis1 trial

Toxic Epidermal Necrolysis1 trial

Tics1 trial

Tic Disorder1 trial

Kidney Transplant1 trial

Pneumonia1 trial

Multiple System Atrophy1 trial

Idiopathic Pulmonary Fibrosis1 trial

Guillain-Barre syndrome1 trial

Hyperbilirubinemia1 trial

Chronic Inflammatory Demyelinating Polyradiculoneuropathy1 trial

Japanese encephalitis1 trial

Efficacy and Safety1 trial

Systemic Sclerosis1 trial

Neuropathic Pain1 trial

Autoimmune Encephalitis1 trial

Myelopathy1 trial

Stem Cell Transplant1 trial

Phase 11 trial

Newly Diagnosed1 trial

End-Stage Renal Disease1 trial

Antibiotic Therapy1 trial

Bronchopulmonary Dysplasia1 trial

Myasthenia Gravis1 trial

Biliary Atresia1 trial

Langerhans Cell Histiocytosis1 trial

COVID-191 trial

Immunotherapy1 trial

Optic Neuritis1 trial

Down syndrome1 trial

References

Drug Info

Quick Facts

Related News